Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

被引：378

作者：

Shields, Ryan K. ^{[1
,3
,4
]}

Potoski, Brian A. ^{[1
,2
,3
]}

Haidar, Ghady ^{[1
]}

Hao, Binghua ^{[4
]}

Doi, Yohei ^{[1
]}

Chen, Liang ^{[6
]}

Press, Ellen G. ^{[1
]}

Kreiswirth, Barry N. ^{[6
]}

Clancy, Cornelius J. ^{[1
,4
,5
]}

Hong Nguyen, M. ^{[1
,3
,4
]}

机构：

[1] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA

[2] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA

[3] Univ Pittsburgh, Antibiot Management Program, Med Ctr, Pittsburgh, PA 15260 USA

[4] Univ Pittsburgh, XDR Pathogen Lab, Med Ctr, Pittsburgh, PA 15260 USA

[5] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA

[6] Rutgers State Univ, New Jersey Med Sch, TB Ctr, Publ Hlth Res Inst, Newark, NJ USA

来源：

CLINICAL INFECTIOUS DISEASES | 2016年 / 63卷 / 12期

关键词：

ceftazidime-avibactam resistance; carbapenem-resistant Enterobacteriaceae; Klebsiella pneumoniae carbapenemase; KLEBSIELLA-PNEUMONIAE; BETA-LACTAMASES; BACTEREMIA;

D O I：

10.1093/cid/ciw636

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

引用

页码：1615 / 1618

页数：4

共 12 条

[1]

Acycaz (Ceftazidime-avibactam), 2016, PRESCR INF

[2]

[Anonymous], HEALTHC ASS INF HAIS

[3]

Centers for Disease Control and Prevention/, 2016, NAT HEALTHC SAF NETW

[4] Epidemiology and Molecular Characterization of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae in Transplant Recipients [J].